Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
-
BioXcel Therapeutics Announces Proposed Public Offering
-
Canaccord Genuity Reiterates Buy Rating on BioXcel Therapeutics (BTAI)
-
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
-
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
-
4 Takeaways from BioXcel Therapeutics (BTAI) Management Meetings, Canaccord Genuity Reiterates Buy
-
BioXcel Therapeutics (BTAI) PT Raised to $84 at Canaccord Genuity
-
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
-
Canaccord Genuity Reiterates Buy Rating on BioXcel Therapeutics (BTAI) Ahead of Top-Line RELEASE Phase 1b/2 Data
-
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference
-
BioXcel Therapeutics (BTAI) PT Raised to $68 at Canaccord Genuity, More Upside Exists
-
BioXcel Therapeutics (BTAI) Prices 2M Share Offering at $32
-
BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock
-
BioXcel Therapeutics (BTAI) to Offer 2M Shares of Common Stock
-
BioXcel Therapeutics Announces Proposed Public Offering of Common Stock
-
Canaccord Genuity Says Buy Post-Offering Pullback in BioXcel Therapeutics (BTAI)
-
BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference
-
BioXcel Therapeutics (BTAI) PT Raised to $24 at Canaccord Genuity
-
BioXcel Therapeutics (BTAI) PT Raised to $24 at Canaccord Genuity
-
BioXcel Therapeutics (BTAI) Reiterated Buy At Canaccord On Rich Catalyst Calendar
-
BioXcel Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
-
Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
-
BioXcel Therapeutics Announces Closing of Initial Public Offering
-
BioXcel Therapeutics Announces Closing of Initial Public Offering
-
BioXcel Therapeutics (BTAI) Files $69M IPO

